Paper Details

  1. Home
  2. Paper Details

HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review.

Author: BouganimNathaniel, Brezden-MasleyChristine, EdwardsScott, GelmonKaren, HenningJan-Willem, HiltonJohn F, JerzakKatarzyna J, SehdevSandeep

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This narrative review provides best-practice recommendations for first-line treatment of HR+/HER2- advanced breast cancer in Canada. Ribociclib + aromatase inhibitor is the preferred treatment for de novo advanced disease or relapse after adjuvant endocrine therapy. Ribociclib or abemaciclib + fulvestrant is preferred for patients with early relapse. Abemaciclib or palbociclib may be used when ribociclib is not suitable. Endocrine therapy alone may be used in cases of contraindication to CDK4/6 inhibitors or limited life expectancy.
Paper Details　
Original Abstract of the Article :
The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2- advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297170/

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of HR+/HER2- Advanced Breast Cancer Treatment

In the vast and ever-evolving landscape of breast cancer treatment, researchers are constantly seeking new and improved therapies. This review delves into the world of HR+/HER2- advanced breast cancer, a type of breast cancer that poses unique challenges for oncologists. The authors provide a comprehensive overview of the latest treatment recommendations, emphasizing the impact of CDK4/6 inhibitors, a class of drugs that have revolutionized treatment strategies. This review serves as a valuable guide for clinicians navigating the complex landscape of HR+/HER2- advanced breast cancer treatment.

A New Dawn in Breast Cancer Treatment

The approval of CDK4/6 inhibitors has significantly improved outcomes for patients with HR+/HER2- advanced breast cancer. The authors highlight the importance of these inhibitors in extending overall survival and progression-free survival. The review provides specific recommendations for first-line treatment based on the stage of the disease and the patient's individual characteristics. This evidence-based approach is crucial in optimizing treatment plans for this complex disease.

Living Well with Advanced Breast Cancer

HR+/HER2- advanced breast cancer can be a daunting diagnosis. However, this research provides a valuable resource for understanding the latest treatment options. By staying informed and consulting with a specialist, patients can actively participate in their care and work towards a brighter future. Remember, there are resources available to help you navigate this journey, and you are not alone.

Dr.Camel's Conclusion

This review offers a comprehensive roadmap for navigating the complexities of HR+/HER2- advanced breast cancer treatment. The emergence of CDK4/6 inhibitors has brought a wave of hope to this challenging disease, offering patients a better chance at survival. It's a reminder that research and innovation are constantly transforming the landscape of cancer care.

Date :
  1. Date Completed 2023-06-29
  2. Date Revised 2023-07-01
Further Info :

Pubmed ID

37366894

DOI: Digital Object Identifier

PMC10297170

Related Literature

Article Analysis
・Effects of ribociclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.